Y-mAbs Therapeutics Inc
YMAB
$15.11
Closing
▼-0.20%
1D
▲121.55%
YTD
Market cap
$662.79M
52 week high
$20.90
52 week low
$4.60
Volume
116,822
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$662.79M
Analysts' Rating
BUY
Price Target (Mean)
12.14286
Total Analysts
7
P/E
Operating Margin
-37.89%
Beta
0.78
Revenue Growth (Annual)
87.03%
52 week high
$20.90
52 week low
$4.60
Div. Yield
%
EPS Annual Growth
28.57
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel, antibody-based therapeutic cancer products. The Company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. Its product pipeline includes DANYELZA (naxitamab-gqgk), which targets tumors that express GD2, and one product candidate at the registration-stage, OMBLASTYS (omburtamab), which targets tumors that express B7-H3. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb) that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas. Omburtamab is a novel murine monoclonal antibody designed for compartmental immunotherapy. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several types of cancers, including pediatric CNS/LM from NB.
